Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Pomalidomide as a Replacement for Lenalidomide for Multiple Myeloma Patients Relapsed or Refractory to a Lenalidomide-Containing Combination Regimen

NCT02188368 is registered in ClinicalTrials.gov with Oncotherapeutics as lead sponsor.

NCT NCT02188368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02188368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Pomalidomide as a Replacement for Lenalidomide for Multiple Myeloma Patients Relapsed or Refractory to a Lenalidomide-Containing Combination Regimen
Lead sponsor
Oncotherapeutics
Phase
Phase 2
Overall status
Terminated
Start date
July 7, 2014
Completion date
October 23, 2020
Enrollment
45 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma